Amiee Marin
Family · Flower Mound, TXNPI 1437632338
Payments from drug & device makers
Across 212 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$361
- Lilly USA, LLC$351
- AstraZeneca$350
- Amgen$215
- Medtronic$193
- Mannkind Corporation$182
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $361 |
| Lilly USA, LLC | 21 | $351 |
| AstraZeneca | 18 | $350 |
| Amgen | 16 | $215 |
| Medtronic | 8 | $193 |
| Mannkind Corporation | 11 | $182 |
| Sanofi-aventis U.S. LLC | 7 | $162 |
| Clarus Therapeutics Inc. | 7 | $152 |
| Xeris Pharmaceuticals, Inc. | 6 | $132 |
| Bayer | 6 | $117 |
| Boehringer Ingelheim | 6 | $116 |
| Merck | 7 | $114 |
| Antares Pharma, Inc. | 6 | $112 |
| Dexcom, Inc. | 6 | $111 |
| Ascensia Diabetes Care US Inc. | 5 | $106 |
| AbbVie | 6 | $104 |
| Amarin Pharma, Inc. | 6 | $101 |
| Tandem Diabetes Care, Inc. | 4 | $79 |
| Sequel Med Tech, LLC | 4 | $71 |
| Cequr Corporation | 3 | $71 |
| IBSA Pharma Inc. | 4 | $68 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Vivus LLC | 4 | $49 |
| Insulet Corporation | 2 | $46 |
| Corcept Therapeutics | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| Boston Scientific | 1 | $35 |
| Alvogen Inc | 2 | $35 |
| Amphastar Pharmaceuticals, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $31 |
| Soleno Therapeutics, Inc. | 1 | $31 |
| Pfizer | 2 | $31 |
| Radius Health, Inc. | 2 | $28 |
| Tolmar, Inc. | 1 | $26 |
| Abbott | 1 | $22 |
| Avvisto Therapeutics, LLC | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$3,887 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $150,401 |
| MounjaroTirzepatide | 32 | $53,846 |
| JardianceEmpagliflozin | 34 | $40,876 |
| TrulicityDulaglutide | 17 | $30,392 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $24,027 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $22,345 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $15,256 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $10,891 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $10,406 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $10,265 |
| NovologInsulin Aspart | 16 | $4,998 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,240 |
| HumalogInsulin Lispro | 12 | $4,157 |
| SynthroidLevothyroxine Sodium | 45 | $3,609 |
| Novolog FlexpenInsulin Aspart | 12 | $3,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $361 | $155,399132 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $351 | $88,39461 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $116 | $51,76750 claims |
| AbbVieSynthroid | $104 | $3,60945 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,446170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Flower Mound
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.